209 related articles for article (PubMed ID: 28198785)
1. EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT: Results of the OASIS Trial ERG Substudy.
Birch DG; Benz MS; Miller DM; Antoszyk AN; Markoff J; Kozma P; Meunier E; Sergott RC;
Retina; 2018 Feb; 38(2):364-378. PubMed ID: 28198785
[TBL] [Abstract][Full Text] [Related]
2. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
[TBL] [Abstract][Full Text] [Related]
3. THE OASIS MP-1 SUBSTUDY: Characterization of the Effect of Ocriplasmin on Microperimetry Parameters.
Sadda SR; Dugel PU; Gonzalez VH; Meunier E; Kozma P
Retina; 2019 Feb; 39(2):319-330. PubMed ID: 29206755
[TBL] [Abstract][Full Text] [Related]
4. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin.
Jackson TL; Regillo CD; Girach A; Dugel PU;
Ophthalmic Surg Lasers Imaging Retina; 2016 Aug; 47(8):716-23. PubMed ID: 27548448
[TBL] [Abstract][Full Text] [Related]
5. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
[TBL] [Abstract][Full Text] [Related]
6. Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole.
Jackson TL; Verstraeten T; Duchateau L; Lescrauwaet B
Acta Ophthalmol; 2017 Dec; 95(8):e740-e745. PubMed ID: 28133919
[TBL] [Abstract][Full Text] [Related]
7. Impact of Preinjection Spectral Domain Optical Coherence Tomography Findings in the Use of Intravitreal Ocriplasmin in a Clinical Setting.
Wertheimer C; Haritoglou C; Laubichler P; Wolf A; Kaessmann K; Schumann RG; Priglinger S; Mayer WJ
Ophthalmologica; 2018; 239(1):11-18. PubMed ID: 28954271
[TBL] [Abstract][Full Text] [Related]
8. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.
Gandorfer A; Benz MS; Haller JA; Stalmans P; Pakola SJ; Girach A; Kampik A; Toth CA; Jaffe GJ;
Retina; 2015 Jun; 35(6):1151-7. PubMed ID: 25741816
[TBL] [Abstract][Full Text] [Related]
9. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
[TBL] [Abstract][Full Text] [Related]
10. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
[TBL] [Abstract][Full Text] [Related]
11. Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis.
Thomas AS; Folgar FA; Jaffe GJ; Toth CA; Mahmoud TH
Ophthalmol Retina; 2019 Jan; 3(1):42-52. PubMed ID: 30929816
[TBL] [Abstract][Full Text] [Related]
12. Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration.
Novack RL; Staurenghi G; Girach A; Narendran N; Tolentino M
Ophthalmology; 2015 Apr; 122(4):796-802. PubMed ID: 25435217
[TBL] [Abstract][Full Text] [Related]
13. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
[TBL] [Abstract][Full Text] [Related]
14. Visual Function Response to Ocriplasmin for the Treatment of Vitreomacular Traction and Macular Hole: The OASIS Study.
Lescrauwaet B; Duchateau L; Verstraeten T; Jackson TL
Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5842-5848. PubMed ID: 29141079
[TBL] [Abstract][Full Text] [Related]
15. Early vitreomacular separation with delayed macular hole closure after ocriplasmin treatment.
Liang IC; Wang K; Chien HW; Lin SY
Indian J Ophthalmol; 2016 Mar; 64(3):222-4. PubMed ID: 27146933
[TBL] [Abstract][Full Text] [Related]
16. [Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin].
Lommatzsch AP; Gutfleisch M; Dietzel M; Heimes B; Spital G; Böhme M; Bornfeld N; Pauleikhoff D
Klin Monbl Augenheilkd; 2014 Sep; 231(9):909-14. PubMed ID: 24788606
[TBL] [Abstract][Full Text] [Related]
17. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
Stalmans P; Benz MS; Gandorfer A; Kampik A; Girach A; Pakola S; Haller JA;
N Engl J Med; 2012 Aug; 367(7):606-15. PubMed ID: 22894573
[TBL] [Abstract][Full Text] [Related]
18. [Initial Clinical Experiences Using Ocriplasmin for the Treatment of Vitreomacular Traction with or without a Macular Hole].
Lenk J; Matthé E; Ventzke S; Pillunat LE; Sandner D
Klin Monbl Augenheilkd; 2018 Jan; 235(1):73-80. PubMed ID: 28282697
[TBL] [Abstract][Full Text] [Related]
19. Short-term changes in posterior vitreous cortex following intravitreal ocriplasmin for symptomatic vitreomacular traction syndrome: a prospective study.
Cacciamani A; Gattegna R; Pileri M; Di Nicola M; Bardanzellu S; Facciolo G; Cosimi P; Govetto A; Scarinci F
Int Ophthalmol; 2020 Jan; 40(1):185-193. PubMed ID: 31565760
[TBL] [Abstract][Full Text] [Related]
20. PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY.
Mein C; Dugel PU; Feiner L; Drenser K; Miller D; Benz M; Meunier E; Moro L; Fineman MS
Retina; 2020 Jul; 40(7):1331-1338. PubMed ID: 31259807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
